Last reviewed · How we verify
Astra Zeneca COVID-19 vaccine
Astra Zeneca COVID-19 vaccine is a viral vector vaccine Biologic drug developed by Vinbiocare Biotechnology Joint Stock Company. It is currently in Phase 2 development for COVID-19 prevention.
This viral vector vaccine delivers genetic instructions for the SARS-CoV-2 spike protein to stimulate adaptive immune responses against COVID-19.
This viral vector vaccine delivers genetic instructions for the SARS-CoV-2 spike protein to stimulate adaptive immune responses against COVID-19. Used for COVID-19 prevention.
At a glance
| Generic name | Astra Zeneca COVID-19 vaccine |
|---|---|
| Sponsor | Vinbiocare Biotechnology Joint Stock Company |
| Drug class | viral vector vaccine |
| Target | SARS-CoV-2 spike protein |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
The vaccine uses a replication-deficient chimpanzee adenovirus (ChAdOx1) as a vector to introduce the gene encoding the SARS-CoV-2 spike protein into host cells. This triggers both cellular (T-cell) and humoral (antibody) immune responses. The immune system then recognizes and attacks cells expressing the spike protein and neutralizes circulating virus.
Approved indications
- COVID-19 prevention
Common side effects
- Injection site pain
- Fatigue
- Headache
- Myalgia
- Fever
- Chills
Key clinical trials
- The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01) (PHASE2, PHASE3)
- Phase II/III Study of the AVX/COVID-12 Vaccine Against COVID-19 Applied as a Booster. (PHASE2, PHASE3)
- Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity (PHASE2)
- Allergy and COVID-19 Vaccines (PHASE3)
- National Cohort Study of Effectiveness and Safety of SARS-CoV-2/COVID-19 Vaccines (ENFORCE) (PHASE4)
- The Safety and Immunogenicity of a DNA-based Vaccine (COVIGEN) in Healthy Volunteers (PHASE1)
- Adaptive Immune Response to COVID-19 Vaccination
- Vaccination Against COVID-19 in Pregnant and Lactating Women in Belgium
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Astra Zeneca COVID-19 vaccine CI brief — competitive landscape report
- Astra Zeneca COVID-19 vaccine updates RSS · CI watch RSS
- Vinbiocare Biotechnology Joint Stock Company portfolio CI
Frequently asked questions about Astra Zeneca COVID-19 vaccine
What is Astra Zeneca COVID-19 vaccine?
How does Astra Zeneca COVID-19 vaccine work?
What is Astra Zeneca COVID-19 vaccine used for?
Who makes Astra Zeneca COVID-19 vaccine?
What drug class is Astra Zeneca COVID-19 vaccine in?
What development phase is Astra Zeneca COVID-19 vaccine in?
What are the side effects of Astra Zeneca COVID-19 vaccine?
What does Astra Zeneca COVID-19 vaccine target?
Related
- Drug class: All viral vector vaccine drugs
- Target: All drugs targeting SARS-CoV-2 spike protein
- Manufacturer: Vinbiocare Biotechnology Joint Stock Company — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for COVID-19 prevention
- Compare: Astra Zeneca COVID-19 vaccine vs similar drugs
- Pricing: Astra Zeneca COVID-19 vaccine cost, discount & access